A
1.23
0.00 (0.00%)
| Penutupan Terdahulu | 1.23 |
| Buka | 1.25 |
| Jumlah Dagangan | 334,412 |
| Purata Dagangan (3B) | 396,931 |
| Modal Pasaran | 121,989,312 |
| Harga / Jualan (P/S) | 3.19 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 20 May 2025 |
| Margin Keuntungan | -197.64% |
| Margin Operasi (TTM) | -123.58% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Nisbah Semasa (MRQ) | 4.46 |
| Aliran Tunai Operasi (OCF TTM) | -136.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.34 M |
| Pulangan Atas Aset (ROA TTM) | -27.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | ADC Therapeutics SA | Bercampur | Bercampur |
AISkor Stockmoo
2.2
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.20 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 21.81% |
| % Dimiliki oleh Institusi | 59.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Prosight Management, Lp | 31 Dec 2024 | 9,515,000 |
| Orbimed Advisors Llc | 31 Dec 2024 | 5,968,451 |
| Vantage Consulting Group Inc | 31 Dec 2024 | 850,737 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.00 (HC Wainwright & Co., 550.41%) | Beli |
| 8.00 (RBC Capital, 550.41%) | Beli | |
| Median | 8.00 (550.41%) | |
| Rendah | 7.00 (Guggenheim, 469.11%) | Beli |
| Purata | 7.67 (523.58%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 1.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 15 May 2025 | 8.00 (550.41%) | Beli | 1.69 |
| Guggenheim | 31 Mar 2025 | 7.00 (469.11%) | Beli | 1.41 |
| HC Wainwright & Co. | 31 Mar 2025 | 8.00 (550.41%) | Beli | 1.41 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PFISTERER THOMAS | - | 1.69 | -451,856 | -763,637 |
| WILD HANS PETER | 1.69 | - | 9,788,944 | 16,543,315 |
| Jumlah Keseluruhan Kuantiti Bersih | 9,337,088 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 15,779,679 | |||
| Purata Pembelian Keseluruhan ($) | 1.69 | |||
| Purata Jualan Keseluruhan ($) | 1.69 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PFISTERER THOMAS | 15 May 2025 | Dibuang (-) | 451,856 | 1.69 | 763,637 | |
| WILD HANS PETER | 15 May 2025 | Diperolehi (+) | 9,788,944 | 1.69 | 16,543,315 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |